Healthcare
Live Price
Offline$2.98
-1.65% today
Window Change
-14.57%
Window
May 5, 2026 โ Jun 24, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 35 bars ยท May 5, 2026 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Can-Fite BioPharma Ltd. (CANF) is a Healthcare stock with a market cap of $8.34B. The stock last traded around $2.98 and down 14.6% across the available one-year price window (May 5, 2026 โ Jun 24, 2026). Baseline metrics include revenue growth of -39.4%, EPS growth of -1013.9%, a dividend yield of 0.0%. What stands out right now is revenue -39.4%, EPS -1013.9%, free cash flow -18.1% with operating margin -1815.2% and ROIC -101.1%. Valuation already assumes a fairly strong business story at price/sales 21884.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CANF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-39.4% vs +7.6% peer median
Operating Margin
Below sector median
-1815.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -39.4% and EPS is at -1013.9%, with operating margin around -1815.2%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CANF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CANF Max Drawdown
-22.53%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CANF and SPY.
Company Overview
Can-Fite BioPharma Ltd.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.